Program Planners – Editor and Section Editors
Mark H. Rapaport, MD, Editor of FOCUS, and Chairman and Chief of Psychiatric Services, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga. No financial relationships with commercial interests.
Dorothy Stubbe, MD, Editor and Author, Communications Commentary, Associate Professor and Program Director, Yale University School of Medicine Child Study Center, New Haven, CT.- No financial relationships with commercial interests.
Laura Dunn, MD, Editor Ethics Column; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA; No financial relationships with commercial interests.
Boadie Dunlop, M.D., Editor, Applied Armamentarium section, Associate Professor of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Director, Mood and Anxiety Disorders Program, Emory University School of Medicine. Dr. Dunlop reports: Consultant: Myriad Neuroscience, Sophren Therapeutics. Grant/Research: Acadia, Aptinyx, Intracellular Therapies, Takeda, Compass Pathways, Sage.
Ian Cook, M.D. Section Editor/author, Patient Management Exercise, Postpartum Depression. Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, and Los Angeles TMS Institute. Dr. Cook reports that the University of California, Los Angeles (UCLA), received research grant funding from NeoSync, Inc., for his work there prior to retirement and that his active biomedical device patents are assigned to the University of California. He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently is on leave as its chief medical officer and senior vice president. Dr. Cook has equity positions and leadership roles in HeartCloud, Inc., and the BrainCloud Corporation.
Authors and Guest Editors
Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?
Jennifer Severe, M.D., John F. Greden, M.D., Priyanka Reddy, Department of Psychiatry, University of Michigan, Ann Arbor. Dr. Greden reports serving on advisory boards or speaker bureaus or as an expert witness or consultant for Clarigent Health, Med-IQ, Inc., Palmetto GBA (MolDX Program), and Sage Therapeutics. The other authors report no financial relationships with commercial interests.
Depression Comorbid with Stroke, Traumatic Brain Injury, Parkinson’s Disease, and Multiple Sclerosis: Diagnosis and Treatment
Susan K. Conroy, M.D., Ph.D., Katherine B. Brownlowe, M.D., Thomas W. McAllister, M.D.Department of Psychiatry, Indiana University School of Medicine, Indianapolis (Conroy, McAllister); Department of Psychiatry, Wexner Medical Center, Ohio State University, Columbus (Brownlowe). Dr. McAllister receives research funding from the National Institutes ofHealth, the U.S. Department of Defense, and the National CollegiateAthletic Association. Dr. Conroy reports that her spouse was employed by Eli Lilly and Company until 2019. Dr. Brownlowe reports no financial relationships with commercial interests.
Care of Patients with Complex Mood Disorders
Zachary A. Cordner, M.D., Ph.D., Dean F. MacKinnon, M.D., J. Raymond DePaulo Jr., M.D., Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore (Cordner, MacKinnon, DePaulo). Dr. DePaulo serves as an unpaid consultant for Assurex Health, Inc. on behalf of the National Network of Depression Centers (NNDC), which is compensated for his consultation; he holds stock in CVS Health; he has a fiduciary but unpaid relationship with the NNDC as Chairperson of the Board of Directors, and he receives travel reimbursement from the NNDC (about $2,500 per year). The other authors report no financial relationships with commercial interests.
Computer-Assisted CBT and Mobile Apps for Depression: Assessment and Integration Into Clinical Care
Jesse H. Wright, M.D., Ph.D., and Matthew Mishkind, Ph.D., Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, Kentucky (Wright); Johnson Depression Center, Department of Family Medicine, University of Colorado School of Medicine, Aurora (Mishkind). Dr. Wright is an author of the Good Days Ahead program and has an equity interest in Empower Interactive and Mindstreet, developers and distributors of the program. He receives no income from program sales. He also reports receipt of book royalties from American Psychiatric Press, Inc., Guilford Press, and Simon and Schuster and receipt of grant support from the Agency for Healthcare Research and Quality and the Oticon Foundation. Dr. Mishkind reports receipt of payments for service on an advisory board for Meta Pro.
Suicide Risk Assessment and Prevention: Challenges and Opportunities
Eileen P. Ryan, D.O., and Maria A. Oquendo, M.D., Ph.D., Department of Psychiatry and Behavioral Health, Ohio State University
College of Medicine, Columbus (Ryan); and Perelman School of Medicine, University of Pennsylvania, Philadelphia (Oquendo). Dr. Ryan receives royalties from Oxford University Press and honoraria from the American Physicians Institute and Northwestern University (Grand Rounds). Dr. Oquendo receives royalties for the commercial use of the Columbia Suicide Severity Rating Scale and owns shares in Mantra, Inc. Her family owns stock in Bristol-Myers Squibb.
Is Postpartum Depression Different from Depression Occurring Outside of the Perinatal Period? A Review of the Evidence
Melissa M. Batt, M.D., M.P.H., Korrina A. Duffy, Ph.D., Andrew M. Novick, M.D., Ph.D., Christina A. Metcalf, Ph.D., C. Neill Epperson, M.D., Department of Psychiatry (all authors) and Helen and Arthur E. Johnson Depression Center (Batt), University of Colorado School of Medicine, Anschutz Medical Campus, Aurora. Dr. Epperson reports that she consults to Sage Therapeutics and serves on the advisory board of Asarina Pharma. She has investments in Abbott, Abbvie, Johnson and Johnson, Merck, and Pfizer. The other authors report no financial relationships with commercial interests.
Advancing Treatment of Depression and Other Mood Disorders Through Innovative Models of Telepsychiatry
Jay H. Shore, M.D., M.P.H., Christopher D. Schneck, M.D., Matthew Mishkind, Ph.D., Robert Caudill, M.D., Marshal Thomas, M.D. Helen and Arthur E Johnson Depression Center, School of Medicine, University of Colorado, Anschutz Medical Campus, Aurora (Shore, Schneck, Mishkind, Thomas); AccessCare, Aurora, Colorado (Shore, Thomas); Department of Psychiatry and Behavioral Sciences, University of Louisville, School of Medicine, Louisville, Kentucky (Caudill). Dr. Shore is chief medical officer of AccessCare, a provider of telemental health services, and has received royalties from Springer Publishing and from American Psychiatric Association Publishing. Dr. Mishkind reports serving on an advisory board for MetaPro. The other authors report no financial relationships with commercial interests.
Management of Complex Co-occurring Psychiatric Disorders and High-Risk Behaviors in Adolescents
Justine W. Welsh, M.D., Maggie Mataczynski, B.A., Dana B. Sarvey, M.D., Jessica E. Zoltani, M.D. Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Welsh and Mataczynski); Adolescent Acute Residential Treatment, McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Sarvey); Yale New Haven Psychiatric Hospital, Yale School of Medicine, New Haven, Connecticut (Zoltani). Dr. Welsh has received consulting fees from Analgesic Solutions and training fees from Chestnut Health Systems. The other authors report no financial relationships with commercial interests.
Next-Step Treatment Considerations for Patients with Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine
William V. Bobo, M.D., M.P.H., Patricio Riva-Posse, M.D., Fernando S. Goes, M.D., Sagar V. Parikh, M.D. Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Florida (Bobo); Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta (Riva-Posse); Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore (Goes); Department of Psychiatry, University of Michigan, Ann Arbor (Parikh). Dr. Riva-Posse served on an advisory board for Janssen Pharmaceuticals. Dr. Goes has received research support from Janssen Pharmaceuticals. Dr. Parikh has received research support from Assurex, Sage, and Takeda; has served as a consultant for Assurex, Janssen, Mensante, and Takeda; and owns shares of Mensante. Dr. Bobo reports no financial relationships with commercial interests.
Ethics Commentary: Ethical Issues in the Evaluation and Treatment of Depression
Alissa Megan Rogol, M.D., J.D., Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California. Dr. Rogol reports no financial relationships with commercial interests.
American Psychiatric Association Staff Involved in Planning:
Tristan Gorrindo, MD Director, Division of Education, APA – no conflicts
Kristen Moeller, Director of CME, Associate Director of FOCUS -- no conflicts